283. Acquired pure red cell aplasia Clinical trials / Disease details

Clinical trials : 18 / Drugs : 42 - (DrugBank : 22) / Drug target genes : 19 - Drug target pathways : 98

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04470804 (ClinicalTrials.gov)	August 1, 2020	9/7/2020	Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study	Pure Red Cell Aplasia, Acquired	Drug: Sirolimus;Drug: Cyclosporine A	Bing Han	NULL	Recruiting	18 Years	70 Years	All	40	Phase 4	China
2	NCT03364764 (ClinicalTrials.gov)	February 1, 2018	21/11/2017	Sirolimus Treatment for Refractory PRCA	Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study	Pure Red Cell Aplasia	Drug: Sirolimus	Bing Han	NULL	Completed	18 Years	80 Years	All	64	Phase 4	China
3	NCT03214354 (ClinicalTrials.gov)	July 5, 2017	5/7/2017	Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor	A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)	Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell Aplasia	Drug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: Sirolimus	University of Calgary	NULL	Recruiting	1 Year	19 Years	All	12	Phase 2	Canada